New Treatment for MOG Antibody Condition
Novel immunotherapy against MOG antibody disease
['FUNDING_SBIR_2'] · EVOQ THERAPEUTICS, INC. · NIH-11136993
This research is developing a new, targeted treatment for people living with MOG antibody disease, a rare neurological condition.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EVOQ THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11136993 on ClinicalTrials.gov |
What this research studies
MOG antibody disease (MOGAD) is a rare neurological condition that can cause vision loss, spinal cord issues, and seizures. Current treatments often involve steroids and immunosuppressants, which can have side effects and may not prevent frequent relapses. This project aims to create a new, more targeted treatment using tiny particles called NanoDiscs. These NanoDiscs are designed to deliver specific signals to the immune system, helping it to stop attacking the body's own MOG protein. The goal is to develop a treatment that specifically targets the cause of MOGAD, offering a better option for patients.
Who could benefit from this research
Good fit: This research is ultimately for individuals diagnosed with Myelin Oligodendrocyte Glycoprotein (MOG) antibody disease who are seeking new treatment options.
Not a fit: Patients without MOG antibody disease would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new approach could offer MOGAD patients a more targeted treatment with fewer side effects and potentially reduce debilitating relapses compared to current therapies.
How similar studies have performed: Preliminary data in animal models of similar autoimmune conditions, like experimental autoimmune encephalomyelitis and type 1 diabetes, has shown promising results with this NanoDisc technology.
Where this research is happening
ANN ARBOR, UNITED STATES
- EVOQ THERAPEUTICS, INC. — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DANIEL, WESTON — EVOQ THERAPEUTICS, INC.
- Study coordinator: DANIEL, WESTON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.